<DOC>
	<DOCNO>NCT00944645</DOCNO>
	<brief_summary>This study evaluate definitive bioequivalence tablet MK0524A ( 1000 mg Extended Release ( ER ) Niacin/ 20 mg laropiprant ) two source .</brief_summary>
	<brief_title>MK0524A Bioequivalence Study ( 0524A-059 )</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Subject good health Subject willing follow study guideline Subject history disease condition might confound result study make participation unsafe</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>